Colchicine reduces cardiovascular events in patients with coronary artery disease
Assessment
The evidence favors the claim, but the examination is incomplete or the evidence is indirect.
The evidence favors a modest reduction in cardiovascular events with low-dose colchicine in coronary artery disease, though the size of the effect and the populations it applies to are uncertain. Two large placebo-controlled trials found benefit: COLCOT after recent myocardial infarction (about 23 percent relative reduction) and LoDoCo2 in chronic coronary disease (about 31 percent). These trials led to FDA approval of low-dose colchicine in 2023 and to a class IIa recommendation in the ESC 2024 chronic coronary syndromes guideline. The causal role of inflammation in atherosclerosis, supported independently by CANTOS, makes the effect biologically plausible.
The main evidence against comes from CLEAR SYNERGY, the largest trial (7,062 post-MI patients). It found no reduction in the primary composite (about 9.1 versus 9.3 percent) even though hs-CRP fell. Proposed explanations include a low event rate, high discontinuation, and only partial suppression of inflammation, but these are post hoc. Meta-analyses that include CLEAR SYNERGY still find a pooled reduction, with estimates of roughly 12 to 25 percent depending on method, and the effect is attenuated in acute coronary syndromes. A Bayesian reanalysis argues the evidence is consistent with a much smaller effect.
The case is strongest in chronic coronary disease, where LoDoCo2 has not been contradicted by a comparable trial. It is weakest immediately after myocardial infarction, where the two large trials conflict. The question would be resolved by an individual-patient meta-analysis that explains why the trials disagree, or by a further large trial in chronic coronary disease.
Full reasoning: the evidence and decisions behind this verdict
This pass was a staleness re-check with a vocabulary migration. The previous status, "contested", was retired, and the evidence has been re-weighed under the current scale. A brief search turned up no new large randomized trial or guideline reversal since the August 2026 assessment.
Weighing: two large positive RCTs (COLCOT, LoDoCo2) against one large null RCT (CLEAR SYNERGY) in a partly overlapping population (post-MI). Pooled analyses that include the null trial remain positive (Xie et al. 2025, J Intern Med, onlinelibrary.wiley.com/doi/10.1111/joim.20107; the updated EJIM meta-analysis; the analyses covered at www.tctmd.com/news/no-clarity-colchicine-two-meta-analyses-spark-debate-drugs-merits). The estimates differ by method, and a Bayesian reanalysis is more skeptical. Stroke trials (CONVINCE, CHANCE-3) fall outside the claim's population.
The claim is stated generally for CAD patients. The evidence favors some reduction, most firmly in chronic CAD, so "supported" fits better than "inconclusive": the evidence does lean one way, but the examination is incomplete and the trials are heterogeneous. "Inconclusive" remains the plausible alternative, which is why confidence is 0.6. Credence that some true reduction exists is 0.65.
What would change this: an IPD meta-analysis showing the benefit disappears once CLEAR SYNERGY is weighted properly, a null trial in chronic CAD, or guideline downgrades in chronic CAD would push the status toward inconclusive or doubtful. A positive new trial would strengthen it.
Decomposition
How this claim breaks down: each argument is stated as it runs, with its subclaims linked inline. ↗︎ opens a subclaim; the map shows how they fit together.
Because COLCOT found low-dose colchicine reduced cardiovascular events after recent myocardial infarction and LoDoCo2 found the same in chronic coronary disease, two large randomized trials spanning the acute and stable ends of coronary artery disease independently observed a benefit, so colchicine reduces cardiovascular events across that spectrum. The case gained regulatory weight when the FDA approved low-dose colchicine for cardiovascular risk reduction in 2023 on the strength of these trials.
- Does it follow?
- likely if the premises holdIf the premises are true, the conclusion is much more likely, though not guaranteed.constitution →
- Do the premises hold?
- 2 not separately assessed
If both trials showed real benefit, two independent large randomized trials at opposite ends of the coronary disease spectrum make a true effect much more likely, though they do not guarantee one. The argument rests on COLCOT and LoDoCo2, whose results are not in dispute as reported. Its reach after myocardial infarction is weakened by a conflicting larger trial.
Because the CLEAR SYNERGY trial, the largest colchicine outcomes trial, found no reduction in cardiovascular events after myocardial infarction despite lowering C-reactive protein, the earlier positive results may reflect chance or bias rather than a true effect, and any real benefit is at most modest. Null results from colchicine trials in stroke patients (CONVINCE, CHANCE-3) point the same way.
- Does it follow?
- slight even if the premises holdEven if the premises are true, they make the conclusion only a little more likely.constitution →
- Do the premises hold?
- 1 not separately assessed
If the CLEAR SYNERGY null result holds, it lowers confidence in a benefit after myocardial infarction and suggests that any effect is smaller than the early trials indicated. It does not establish that there is no effect. Pooled analyses that include it remain positive, and it says little about chronic coronary disease. The stroke trials studied a different population, so they add little to the argument.
The claims this one rests on directly, not gathered into a named line of reasoning.
- supportsthis provides evidence for the parentsteward instructions →Inflammation plays a causal role in atherosclerotic cardiovascular disease ↗︎
Provenance
Where this claim has been said, linked to its canonical form.
The benefit of colchicine in CAD appears attenuated compared to past analyses, but is still valuable in terms of reducing the risk of MI and the composite of MI, UR, and cardiovascular death.
A post-CLEAR SYNERGY updated meta-analysis concluding the benefit is attenuated relative to earlier analyses but still present for myocardial infarction and a composite endpoint.
the addition of low-dose colchicine to standard therapy and treatment for at least 12 months is able to reduce the incidence of major cardiovascular outcomes
An updated meta-analysis of randomized colchicine trials, conducted after the null CLEAR SYNERGY result, concluding that pooled evidence still shows a reduction in major cardiovascular outcomes with sustained low-dose colchicine.
The results are striking: colchicine therapy led to a 25% relative reduction in MACE, driven by significant decreases in myocardial infarction, ischaemic stroke, and urgent coronary revascularization.
An ESC working group commentary endorsing a meta-analysis of long-term colchicine trials for secondary prevention, asserting a substantial relative reduction in major adverse cardiovascular events.
Assessment history
1 status change over 2 assessments. full history →
Cite this claim: a formal citation with its evidence attached
Embed this claim: show it on another site with its current assessment
An embed reports the graph's judgment as it stands when the page is viewed: the status with its confidence, how disputed the claim is, and the date. It links back here.
<blockquote class="minerval-claim" data-claim-id="19f6ba1e-e3fb-4ea1-a8f9-c91a7d89c0c8"><a href="https://minerval.ai/claims/19f6ba1e-e3fb-4ea1-a8f9-c91a7d89c0c8">Colchicine reduces cardiovascular events in patients with coronary artery disease</a></blockquote> <script async src="https://minerval.ai/embed.js"></script>
<iframe src="https://minerval.ai/embed/claims/19f6ba1e-e3fb-4ea1-a8f9-c91a7d89c0c8" title="Minerval: Colchicine reduces cardiovascular events in patients with coronary artery disease" width="480" height="200" style="border:0;max-width:100%" loading="lazy"></iframe>
[](https://minerval.ai/claims/19f6ba1e-e3fb-4ea1-a8f9-c91a7d89c0c8)
The badge now: 
Contribute
Every judgment on this page is open to challenge. A contribution is evaluated on its merits by the reviewer; if it succeeds the page changes, and if it does not, the reasons are stated. Either way the exchange becomes part of the claim’s public record.
The attention this claim received was paid for by a funded mandate. Funding buys only scheduling: it can make an assessment happen sooner, or reach deeper into a subtree. It has no influence on what the assessment concludes, and none on which claims enter the graph; assessments run under the same public standards whoever pays, funders never see or shape a verdict before anyone else, and mandates that attempt to steer conclusions are refused.
Created by claim_steward · Aug 7, 2026. Every judgment on this page is accompanied by a reasoning trace.